<DOC>
	<DOCNO>NCT00382590</DOCNO>
	<brief_summary>Primary Objective : 1 . To evaluate whether 5 azacytidine ( 5-aza ) /valproic acid ( VPA ) low dose ara-C produce longer event free survival time patient age &gt; = 60 year untreated Acute Myeloid Leukemia ( AML ) high risk Myelodysplastic Syndrome ( MDS ) typically ineligible , place , study new agent . Secondary Objective : 1 . To evaluate whether pre-treatment methylation/acetylation status AML/MDS blast predict response either therapy whether ability 5 azacytidine + valproic acid combination induce demethylation acetylation parallel response .</brief_summary>
	<brief_title>Azacytidine With Valproic Acid Versus Ara-C Acute Myeloid Leukemia ( AML ) / Myelodysplastic Syndrome ( MDS ) Patients</brief_title>
	<detailed_description>5-aza chemotherapy drug activity leukemia MDS . Researchers hope VPA increase effect 5-aza . Low-dose Cytarabine ( ara-C ) consider standard care treatment leukemia MDS old patient eligible therapy . Before start treatment study , call `` screening test . '' These test help doctor decide eligible take part study . You blood draw ( 2 teaspoon ) routine test . You also bone marrow biopsy aspiration perform . To collect bone marrow biopsy/aspirate , area hip chest bone numb anesthetic , small amount bone marrow bone withdrawn large needle . Women able child must negative blood urine pregnancy test . If find eligible take part study , randomly assign ( toss coin ) one two treatment group . Participants one group receive 5-aza VPA . Participants group receive ara-C alone . At first , equal chance assign either group . As study go along , however , chance assign treatment work best far increase . Participants 5-aza VPA group receive 5-aza injection skin day 7 day row . On 7 day , participant group also take VPA mouth twice day 3 time day base weight . Seven ( 7 ) day consider 1 treatment cycle . Both drug take time . Cycles repeat every 4 6 week . Participants ara-C group receive ara-c twice day injection skin 10 day ( 1 cycle ) . Cycles repeat every 4 6 week . You monitor routine blood test ( 1-2 teaspoon time ) 2-3 time week study . You may receive 12 cycle therapy . You may take study early disease get bad intolerable side effect occur . Once go study , standard follow-up require primary physician . This investigational study . 5-aza approved FDA MDS . VPA approve FDA epilepsy . Their use together study experimental . Ara-C approve acute myelogenous leukemia . About 70 patient take part study . All enrol M. D. Anderson .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Azacitidine</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>1 . Patients must untreated AML , untreated MDS &gt; 10 % blast marrow blood . 2 . They must least age 60 . 3 . They must either serum creatinine &gt; 1.9 mg/ml , serum bilirubin &gt; 1.9 mg/ml , Zubrod performance status 3 4 . 4 . Alternatively , must candidate protocol high priority . 5 . They must provide write consent . 1 ) Must cytogenetic abnormality inv ( 16 ) , ( 16 ; 16 ) ( 8 ; 21 ) , ( 15 ; 17 ) . The relatively good prognosis patient finding warrant use 5 azacytidine , + valproic acid lowdose araC ( LDAC ) .</criteria>
	<gender>All</gender>
	<minimum_age>60 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>Acute Myelogenous Leukemia</keyword>
	<keyword>AML</keyword>
	<keyword>Myelodysplastic Syndrome</keyword>
	<keyword>Leukemia</keyword>
	<keyword>MDS</keyword>
	<keyword>Azacytidine</keyword>
	<keyword>5-Azacytidine</keyword>
	<keyword>5-aza</keyword>
	<keyword>Vidaza</keyword>
	<keyword>5-AZC</keyword>
	<keyword>AZA-CR</keyword>
	<keyword>Ladakamycin</keyword>
	<keyword>Ara-C</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Cytosar</keyword>
	<keyword>DepoCyt</keyword>
	<keyword>Cytosine arabinosine hydrochloride</keyword>
	<keyword>Valproic Acid</keyword>
	<keyword>VPA</keyword>
	<keyword>Depakene</keyword>
</DOC>